Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There seems to be a bit of interest over the last few days. A few chunky buys going through. The may some life in the old dog yet!
Great to see Director Buys around this level.
Thanks, Shandy!
good spot Chris. c30% rise in last 2 days on back of SKIN deal. Well done for joining the dots
just me then. No biggie, I am often the first and then they come...at..much...higher...prices. haha
Part 2
Matthew Bayfield, CEO of Parity Group, added that his company was "pleased" to be partnering with Integumen and rolling out the Drive4Growth AI platform to its client base.
"We have been working with many of the same clients for 45 years, so we understand their needs.
"With healthcare sector data growth in 2020 expected to double every 73 days, our clients need to securely manage and extract greater value using analytics and AI in order to make important decisions," Bayfield explained.
"The Drive4Growth AI platform delivers on those requirements, increases revenue per client, increases client contract term and generates a higher margin, leading to greater profitability."
Part 1
Sharecast News) - Integumen has signed heads of terms with Parity to enter a multi-year framework agreement to be completed on or before 18 December, it announced on Wednesday, for the supply of artificial intelligent (AI) software across Parity's NHS, central government and private institutional clients.
The AIM-traded firm said the agreement would create an opportunity to cross-sell intelligent data management, with a focus on proving return on investment to Parity's more-than-150 institutional clients.
It said the software included full GDPR compliance, with secure cloud data migration from existing legacy systems to a digital workplace through the encrypted 'Drive4Growth' AI platform, powered by Integumen's 'Rinodrive'.
The company said the deal would bring recurring shared revenue streams for both Parity and Integumen in 2020, and provide a value-added proposition in demand from Parity clients, with three-to-five year annual contracts.
It would also give it "immediate access" to 150 public and private institutional clients, with Parity being described as a trusted approved vendor for government and the private sector for more than 45 years.
In May, Integumen acquired Rinocloud for £3m, to enable its 'LabskinAI' platform to use Rinodrive AI to provide cloud-based data services to Integumen's top 20 global skincare clients.
By the end of June, Rinocloud reached monthly profitability, and over the last six months it exceeded revenue from Labskin in the current financial year.
Looking ahead, Integumen said that since 2018, it had seen average sales grow from £5k for consumable, one-off sales to 2019 average sales of £50k as a service contract.
Heading into 2020, the company said it was engaging with multiple top 20 global skin and personal care companies, and believed average sales were likely to range between £100k to £500k for data-as-a-service to skincare research and development framework multi-year agreements, providing "good visibility" of revenue.
As a result, excluding developments that could arise from Integumen entering into the agreement with Parity Group, the company said it was guiding 2020 revenues of £4m.
"We are delighted to be able to roll-out the Drive4Growth AI platform in partnership with the credibility and reputation that Parity data experts hold, with an extensive, if not exhaustive, list of public and private institutions," said Integumen chief executive officer Gerard Brandon.
"We look forward to working alongside Parity to extract greater value for their clients and contribute to the transformation of the UK's National Health Service, public and private institution data over the next few years."
I think once the penny drops this will move up considerably
:-)
Sorry to hear of your loss...haven't we all....It certainly seems strange that there is still some interest in PTY....worth keeping on the watchlist anyway.....I'm also into a silver/gold play with HOC and doing good with that....am only in 2 others OXB, don't know why it is dropping so is on hold and am into SPI as I think it may be a takeover target, it has suffered a bit of late being a health play but I'm not under water with it and it could be a double play from here....take care MrB speak soon...
Dropped out a few days ago, having bought 200,000 back in a while back. I couldn´t see anything exciting from the ceo´s latest update. He seems to be implying the new digital guys have one over on him. I think he is probably right. I´ve worked in freelance IT for 35 years. IR35 is riuning the market I can´t see things getting better. I lost a small amount, I also dropped out of PFC and have gone silver/gold in rather a major way! What about yourself? I was only prompted to look at the bulleting board because my shares seem to have been hovered up by our old friend Timothy Watts the man from Coventry straight away. I still think Helium Switzerland may be up to something.
Are you still in here MrB…..?
New CEO with a good track record who aims to restore margins on their £80m/£90m turnover to at least 5%, ie £4m - £4.5m profit against a market cap of just £8m.
So Helium and Watts have both increased their holdings, Watts by about 2%. I wonder what they see that others don't?
Been in for over 5. Yrs, lost money, disollusioned, whenever it seems like they may be able to bring it together there is immediately another warning. The only reason i´m still in is because there are a few people who seem to be building agood stakes. And the minute it looked as though things might be going better the bod awarded the,selves a boat load of free options based on what, at the time seemed like, not to challenging targets. Given what they have done for the investor over the ladt 7 years i.e seriously eroded capital I don´t really think it was time to pat themselves on the back last May. Their marginns should be better and theyshould be getting better contracts. They should put this company on a good dividend footing before helping them selves to the kitty in my opninion.
Hi MrBond007, I though Rommel was doing a reasonable job at tidying Parity up. I'm wondering if he walked or was forced to walk the plank after a board room bust up! What would have been the red lines to make him leave so suddenly? Plenty to ponder about, but with no succession plans indicated then it donsesn't look good to me.
I´m glad. I didn´t think those options they awarded themselves last year were deserved anyway.
No great surprise there then.
Hi MrB…...good move jumping back in and Lloyds on the up too (if they sort Brexit then the Banks should do well)…..I will carry on watching to see if the bottom line improves before jumping in myself though.....CAPC report tomorrow and my dilemma is sell today and get ready to jump back in tomorrow or hold for good result news.....now where did I put that crystal ball I wonder.....
Yes... thanks. So 4 key investors (albeit one a fund based in Switzerland) now hold 33% of the stock. Approx 40% also held by stockbrokers. As for the board, considering their not inconsiderate remuneration packages, they don´t seem to be very interested in making much in the way of share purchases, IMO, rather relying on share options to vest, And we wonder why there isn´t more interest in the company from potential investors. Here´s hoping for a takeover on reasonable terms for the PI´s. Goodbye B
MrBond, it may have been Timothy Watts taking his holding above 9%.
Looks like the buyer(s). Are in today. Wonder if it’s one of the recent notifiersupping their stake or new entrants?
Just jumped back into PFC.
reasonably positive update. More data analytics seems a good way to proceed. Happy to hold.
IT services and recruitment company Parity is probably the biggest disappointment of the five recommendations. Diurnal always had a high level of risk, so a volatile share price had to be expected. Parity, though, appeared to have good recovery/growth potential and an impressive ability to generate cash.
Parity even won a large contract earlier this year, but contract delays have hampered the progress of the consultancy business. This led to the 2018 pre-tax profit forecast being more than halved to £850,000. That represents breakeven in the second half. Net debt is expected to fall from £1.6 million to £1.2 million.
On the bright side, the non-core activities have finally been sold, albeit for below their net asset value.
The 2019 profit forecast was also cut by around one-quarter to £1.65 million. That would mean that the shares are trading on less than six times prospective 2019 earnings. It appears that a dividend is still some way off.
The strategy remains the same with higher margin consultancy business becoming increasingly important over the medium-term. Non-executive director David Firth has doubled his stake since the profit warning to 200,000 shares. Investor confidence will need to be rebuilt, but the shares appear cheap.
https://www.ii.co.uk/analysis-commentary/aim-tips-2018-game-two-halves-ii507387